Secura Bio, Inc. presents new data on duvelisib treatment for peripheral T-cell lymphoma and announces phase 3 trial plans.

Dec 09, 2024•about 1 year ago

Las VegasTherapeuticsPharmaceuticalBiotechnologyHealth Care

Product Description

Secura Bio, Inc. has shared data from its phase 2 PRIMO trial showing encouraging response rates for duvelisib in treating relapsed or refractory peripheral T-cell lymphoma, alongside plans for a phase 3 trial.

Company Information

Company

Secura Bio

Location

Las Vegas, Nevada, United States

About

Secura Bio is an integrated, commercial-stage pharmaceutical company dedicated to the worldwide commercialization of significant oncology therapies for physicians and their patients. Its product, COPIKTRA®, is currently approved for the treatment of multiple B-cell malignancies and is also being developed for the treatment of peripheral T-cell lymphoma, for which it has received Fast Track status in the United States and is being investigated in combination with other agents through investigator-sponsored studies.

Product Launch Insights

Based on market data

Market expansion signals

New product launches often coincide with market expansion initiatives

Secura Bio, Inc. presents new data on duvelisib treatment for peripheral T-cell lymphoma and announces phase 3 trial plans.

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Related People

Company Information